Abstract |
To assess the effect of treatment of vaginal infections on vaginal shedding of cell-free human immunodeficiency virus type 1 (HIV-1) and HIV-1-infected cells, HIV-1-seropositive women were examined before and after treatment of Candida vulvovaginitis, Trichomonas vaginitis, and bacterial vaginosis. For Candida (n=98), vaginal HIV-1 RNA decreased from 3.36 to 2.86 log(10) copies/swab (P<.001), as did the prevalence of HIV-1 DNA (36% to 17%; odds ratio [OR], 2.8; 95% confidence interval [CI], 1.3-6.5). For Trichomonas vaginitis (n=55), HIV-1 RNA decreased from 3.67 to 3.05 log(10) copies/swab (P<.001), but the prevalence of HIV-1 DNA remained unchanged (22%-25%; OR, 0.8; 95% CI, 0.3-2.2). For bacterial vaginosis (n=73), neither the shedding of HIV-1 RNA (from 3.11 to 2.90 log(10) copies/swab; P=.14) nor the prevalence of DNA (from 21% to 23%; OR, 0.8; 95% CI, 0.3-2.0) changed. Vaginal HIV-1 decreased 3.2- and 4.2-fold after treating Candida and Trichomonas, respectively. These data suggest that HIV-1 transmission intervention strategies that incorporate diagnosis and treatment of these prevalent infections warrant evaluation.
|
Authors | C C Wang, R S McClelland, M Reilly, J Overbaugh, S R Emery, K Mandaliya, B Chohan, J Ndinya-Achola, J Bwayo, J K Kreiss |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 183
Issue 7
Pg. 1017-22
(Apr 01 2001)
ISSN: 0022-1899 [Print] United States |
PMID | 11237825
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-Bacterial Agents
- Antitrichomonal Agents
- DNA, Viral
- RNA, Viral
- Nystatin
- Metronidazole
|
Topics |
- Adult
- Anti-Bacterial Agents
(therapeutic use)
- Antitrichomonal Agents
(therapeutic use)
- Candidiasis
(complications, drug therapy)
- DNA, Viral
(analysis)
- Down-Regulation
- Female
- HIV Infections
(complications, transmission, virology)
- HIV Seropositivity
(complications, virology)
- HIV-1
(genetics, isolation & purification)
- Humans
- Metronidazole
(therapeutic use)
- Nystatin
(therapeutic use)
- Odds Ratio
- Prospective Studies
- RNA, Viral
(analysis)
- Trichomonas Vaginitis
(complications, drug therapy)
- Vagina
(pathology, virology)
- Vaginitis
(complications, drug therapy, microbiology)
- Vaginosis, Bacterial
(complications, drug therapy)
- Virus Shedding
(drug effects)
|